<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	Methods section; Paragraph 3 and 4.	
name, catalogue number and RRID, if available.		

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.	No Cell lines was used in the present study.	
Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		
Primary cultures: Provide species, strain, sex of	No primary cultures were used in the present study.	
origin, genetic modification status.	,	

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,	No laboratory animals were used in the present study.	
genetic modification status. Provide accession		
number in repository OR supplier name, catalog		
number, clone number, OR RRID		
Animal observed in or captured from the	No animals were used in the present study.	
field: Provide species, sex and age where		
possible		
Model organisms: Provide Accession number	No model organisms were used in the present study.	
in repository (where relevant) OR RRID		

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	No plants were used in the present study.	
Microbes: provide species and strain, unique accession number if available, and source	No Microbes were used in the present study.	

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	Acknowledgments section, Ethical Statement.	
equivalent committee(s), provide reference number		
for approval.		
Provide statement confirming informed consent	Acknowledgments section, Ethical Statement.	
obtained from study participants.		
Report on age and sex for all study participants.	Results section; Paragraph 1.	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	This is not clinical trial.	
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.	Methods section; Paragraph 3 and 4.	
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.		
Sample size determination	Methods section; Paragraph 1.	
Randomisation	This is not a blinding study.	
Blinding	This is not randomization.	
Inclusion/exclusion criteria	Methods section; Paragraph 1.	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Methods section; Paragraph 3 and 4.	II/a
Define whether data describe technical or biological replicates	Methods section; Paragraph 3 and 4.	
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Acknowledgments section, Ethical Statement.	.,, u
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Acknowledgments section, Ethical Statement.	
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Acknowledgments section, Ethical Statement.	
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	This is not a dual use research.	.,, 3

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is	Methods section; Paragraph 5.	
excluded, and whether the criteria for exclusion were		
determined and specified in advance.		

Statistics	Yes (indicate where provided: section/paragraph)	n/a	ì
Describe statistical tests used and justify choice of	Methods section; Paragraph 5.		
tests.			ì

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,	This study did not use dataset.	
including protocols for access or restriction on		
access.		
If data are publicly available, provide accession	This study did not use dataset.	
number in repository or DOI or URL.		
If publicly available data are reused, provide	This study did not use dataset.	
accession number in repository or DOI or URL, where		
possible.		

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.	This study did not use code.	
If code is publicly available, provide accession	This study did not use code.	
number in repository, or DOI or URL.		

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: http://dx.doi.org/10.21037/tlcr-21-62